SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation

Stopped early · Not applicable · Has a placebo group

Conditions studied: Smith-Lemli-Opitz Syndrome

In brief

The purpose of this study is to determine if simvastatin improves development and behavior in patients with Smith Lemli-Opitz syndrome (SLOS) receiving dietary cholesterol supplementation.

Key facts

Study ID

NCT01434745

Run by

Oregon Health and Science University

People needed

1

Starts

2011-09-01

Expected to finish

2014-10-01

Last updated by the study team

2019-10-01

Who can join

Age: 1 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female over 1 years old
• Subject has confirmed diagnosis of Smith-Lemli-Opitz Syndrome
• Subject is currently receiving cholesterol supplementation

You may not qualify if…

• Subjects too ill to travel to the study site
• Subjects who are unable to safely undergo study procedures
• Pregnant women

Where it is running

• Oregon Health and Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.